Choose Your Language

Selecting language below will change the language for Insidescompany.com

English Français Dansk Español Deutsche Italiano
Nederlands
Svenska Polski Türk 日本語 Português

The Insides Company is a leading provider of chyme reinfusion solutions for intestinal failure

Tweets by InsidesCompany

The Insides™ Company's flagship product, The Insides™ System, is a medical device that enables chyme to be reinfused into the intestine for enterostomy and enterocutaneous fistula patients.

The Insides™ System is commercially available in the United Kingdom, Europe, and New Zealand.

*The Insides™ System is not available in other markets.‍

The Insides™ System has won GOLD at the 2021 MDEAs in the Gastrointestinal and Genitourinary Devices category

Supplying the world’s leading centres for intestinal failure & rehabilitation

The Insides™ Company is founded by world-leading pioneers in gut nutrition, and commercialised by med-tech veterans. The Insides System is now being used in multiple key international intestinal failure sites.

Please contact us today to learn about how The Insides System can impact your patient's journey to recovery.

Professor Ian Bisset
Co-Founder & Chief Medical Officer

Professor
Greg O’Grady
Co-Founder & Chief Scientific Officer

“The Insides System is revolutionising recovery times & patient well-being.”

For the effective chyme reinfusion treatment of enterocutaneous fistulas and high-output enterostomies

*The Insides™ System is not available in other markets.

Under the standard care pathway, patients recovering from colorectal surgery often have an enterostomy created to divert intestinal contents (chyme) away from the surgical site as it heals.

The enterostomy is typically left open for 6-12 months, and during this time, the chyme that is collected is disposed which can result in intestinal failure

The Insides System, is a chyme reinfusion solution, which enables diverting enterostomy, and enterocutaneous patients to reinfuse chyme back into their intestine, allowing them to recommence oral feeding and reduce length of stay in hospital.

Key Clinical Benefits of Chyme Reinfusion

Earlier return to oral feeding1

Patients able to recommence oral feeding

Improved nutritional outcome2

Increase in nutritional risk index by 10.9 (± 9.5) with a 85% reduction in intestinal losses

Improved restoration of gut function3

Limiting gut atrophy and inflammation

Improved renal function4-5

Prevents dehydration and reduces the potential for chronic kidney disease

Improved liver function5-6

53% reduction in plasma liver test abnormalities

Wean off Parenteral Nutrition6

>91% of patients weaned off parenteral nutrition within a median of 2 days (± 9)

1. Sharma P, Davidson R, Davidson J, Keane C, Liu C, Ritchie SR, et al. Novel chyme reinfusion device for gastrointestinal fistulas and stomas: feasibility study. Br J Surg [Internet]. 2020 Apr 18; Available from:
http://doi.wiley.com/10.1002/bjs.11516
2. Picot D, Layec S, Dussaulx L, Trivin F, Thibault R. Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: A 15-year prospective cohort in a referral centre. Clin Nutr [Internet]. 2017 Apr;36(2):593–600. Available from: https://linkinghub.elsevier.com/retrieve/pii/
S0261561416300668
3. Pflug AM, Utiyama EM, Fontes B, Faro M, Rasslan S. Continuous reinfusion of succus entericus associated with fistuloclysis in the management of a complex jejunal fistula on the abdominal wall. Int J Surg Case Rep [Internet]. 2013;4(8):716–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/
S221026121300179X
4. Fielding A, Woods R, Moosvi SR, Wharton RQ, Speakman CTM, Kapur S, et al. Renal impairment after ileostomy formation: a frequent event with long‐term consequences. Color Dis [Internet]. 2019 Oct 17;codi.14866. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1
111/codi.14866
5. Dilke, S. M., Gould, L., Yao, M., Souvatzi, M., Stearns, A., Ignjatovic-Wilson, A., Tozer, P., & Vaizey, C. J. (2021). Distal feeding–bowel stimulation to treat short-term or long-term pathology: a systematic review. Frontline Gastroenterology, 12(7), 677–682. https://doi.org/10.1136/flgastro-2019-101359
6. Layec S, Seynhaeve E, Trivin F, Carsin-Mahé M, Dussaulx L, Picot D. Management of entero-atmospheric fistulas by chyme reinfusion: A retrospective study. Clin Nutr [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/
S0261561420301485
‍